Cymbalta
Product Images NDC 0002-3240

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 0002-3240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Cymbalta 01)

Chemical structure diagram showing the molecular structure of duloxetine hydrochloride, the active ingredient in Cymbalta by Eli Lilly and Company.*

FDA Label Image

Figure 3 (Cymbalta 02)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline for Cymbalta at different dosages (20 mg QD, 60 mg QD, 60 mg BID) and placebo. The y-axis shows the percentage of patients improved from 0 to 100%, and the x-axis shows pain improvement percentage from 0 to 100%. The lines indicate higher patient improvement with Cymbalta compared to placebo across all percent improvements in pain.*

FDA Label Image

Figure 4 (Cymbalta 03)

A line graph depicting the percentage of patients improved based on percent improvement in pain from baseline. The graph compares three groups: CYM 60mg BID, CYM 60mg QD, and placebo. The x-axis represents percent improvement in pain from 0 to 100, and the y-axis represents the percentage of patients improved from 0% to 100%. CYM groups consistently show higher patient improvement percentages compared to placebo across the pain improvement spectrum.*

FDA Label Image

Figure 5 (Cymbalta 13)

A line graph depicting the percentage of patients improved relative to the percent improvement in pain from baseline. It compares three groups: Cymbalta 60mg taken twice daily, Cymbalta 60mg taken once daily, and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved.*

FDA Label Image

Figure 6 (Cymbalta 14)

A line graph showing the percentage of patients improved by different levels of percent improvement in pain from baseline. It compares four groups: CYM 120mg once daily, CYM 60mg once daily, CYM 20mg once daily, and placebo, illustrating their relative effectiveness over a range of pain improvement percentages.*

FDA Label Image

Figure 7 (Cymbalta 15)

A line graph comparing the percentage of patients improved in pain from baseline (BOCF) between placebo and Cymbalta (120 mg once daily). The x-axis represents percent improvement in pain ranging from >0 to 100, and the y-axis represents the percentage of patients improved, ranging from 0 to 100%. The Cymbalta group consistently shows higher percentages of improvement compared to placebo across all pain improvement thresholds.*

FDA Label Image

Figure 8 (Cymbalta 16)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Cymbalta 60 mg once daily. The graph shows higher patient improvement percentages associated with Cymbalta across increasing levels of pain improvement.*

FDA Label Image

Figure 9 (Cymbalta 17)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline (BOCF) for two groups: Placebo and CYM60/120 mg once daily. The graph shows a downward trend in patient improvement percentages as the percent improvement in pain increases, with CYM60/120 mg once daily generally showing higher percentages of patient improvement than placebo.*

FDA Label Image

Figure 1 (Cymbalta 18)

A line graph comparing the proportion of patients with relapse over time from randomization in days for treatments with Cymbalta versus placebo. The X-axis represents days from randomization to relapse, and the Y-axis represents the proportion of patients with relapse. The graph shows two curves: one dashed line for placebo and one solid line for Cymbalta, illustrating relapse trends over approximately 200 days.*

FDA Label Image

Figure 2 (Cymbalta 19)

A line graph comparing the proportion of patients with relapse over time (days) from randomization, illustrating treatment effects of Cymbalta versus placebo. The x-axis represents time in days up to 300, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. Cymbalta is represented by a solid line showing lower relapse proportions than the placebo, which is represented by a dashed line.*

FDA Label Image

Cymbalta 20

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for Cymbalta 60 mg once daily and placebo. The graph shows two curves, one for Cymbalta and one for placebo, with Cymbalta consistently showing higher patient improvement across various thresholds of pain improvement.*

FDA Label Image

Cymbalta 20mg Contain 049 01

Cymbalta delayed-release capsules label showing 20 mg strength. The label states each capsule contains 22.4 mg of duloxetine hydrochloride equivalent to 20 mg duloxetine. Packaging includes 60 capsules. Labeler is Eli Lilly and Company. The label includes storage instructions, dispensing information, barcode, and a capsule image.*

FDA Label Image

Cymbalta 30mg Contain 063 02

Cymbalta delayed release duloxetine capsules 30 mg label showing 30 capsules in the package. The label includes the NDC 0002-3240-30, dosage information with each capsule containing 33.7 mg duloxetine hydrochloride equivalent to 30 mg duloxetine, and note that it is Rx only. It also features the Eli Lilly and Company logo and standard storage instructions.*

FDA Label Image

Cymbalta 60mg Contain 052 01

Cymbalta delayed release duloxetine capsules 60 mg label from Eli Lilly and Company. The label indicates 30 capsules per bottle with each capsule containing 67.3 mg duloxetine hydrochloride equivalent to 60 mg duloxetine. The product is marked Rx only and includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.